Foscarnet salvage therapy for patients with latestage HIV disease and multiple drug resistance
|
|
- Shon Wright
- 5 years ago
- Views:
Transcription
1 Antiviral Therapy 11: Foscarnet salvage therapy for patients with latestage HIV disease and multiple drug resistance Ana Canestri 1, Jade Ghosn 1, Marc Wirden 2, Françoise Marguet 1, Nadine Ktorza 1, Imane Boubezari 1, Stéphanie Dominguez 1, Philippe Bossi 1, Eric Caumes 1, Vincent Calvez 2 and Christine Katlama 1 * 1 Département des Maladies Infectieuses, Hôpital Pitié-Salpétriêre, Paris, France 2 Département de Virologie, Hôpital Pitié-Salpétriêre, Paris, France *Corresponding author: Tel: ; Fax: : christine.katlama@psl.ap-hop-paris.fr Objective: To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance. Methods: Three drugs experienced patients with plasma viral load (pvl) >50,000 copies/ml and CD4 + T-cell counts <100/mm 3 were eligible for this open-label, single-arm, add-on pilot study. Foscarnet induction therapy consisted of 5 g intravenously twice daily for 6 weeks, in addition to a stable antiretroviral regimen. Patients with at least 1 log 10 decrease in pvl at week 6 (W6), were given foscarnet 5 g intravenously twice daily on two consecutive days each week. Primary endpoint was the virological response rate at W6. Results: Eleven patients were enrolled with a median baseline pvl at 5.16 log 10 copies/ml, median CD4 + T-cell count at 10/mm 3 and median number of mutations of 9, 2 and 12 associated with resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-nrtis and protease inhibitors, respectively. One patient discontinued foscarnet at W2 because of renal toxicity. In an intentto-treat analysis, the median change in pvl from baseline was log 10 copies/ml at W2 and log 10 copies/ml at W6. Eight out of eleven patients had a fall in pvl of at least 1 log 10 at W6, and six started maintenance therapy. The median fall in pvl after 12 weeks of maintenance therapy was log 10 copies/ml in the four patients who reached W12, and the median increase of CD4 + T-cell count was 60/mm 3. Conclusion: In patients with HIV mutations conferring resistance to all antiretroviral drug classes, foscarnet markedly reduced plasma HIV load and improved immunological status. Introduction Many patients with long-standing HIV infection have multidrug resistance. Virological failure remains frequent despite the arrival of new agents like enfuvirtide and tipranavir, and investigational drugs such as TMC-114 [1 5]. In trials of salvage treatments, the proportions of patients who had at least a 1 log 10 reduction in plasma viral load (pvl) at week 24 (W24) were 43% in the Toro study [1], 41% in the RESIST study [4] and 77% in the POWER study [5]. These studies showed that lower baseline pvls were associated with better virological responses. In another study, one-third of patients with viruses resistant to three drug classes died or had new AIDS-defining events during follow-up [6]. Foscarnet, a pyrophosphate analogue, prevents pyrophosphate exchange and thereby inhibits DNA chain elongation catalysed by a variety of viral DNA polymerases (cytomegalovirus [CMV], herpes simplex virus, varicella-zoster virus, Epstein-Barr virus), including HIV-1 reverse transcriptase (RT) [7]. Thymidine-associated mutations (TAMs) appear to render HIV hypersusceptible to foscarnet in vitro [8,9]. In the pre-highly active antiretroviral therapy (HAART) era, foscarnet was mostly given to patients with CMV infection and was found to lower plasma HIV RNA levels [10 14], but its intravenous administration and nephrotoxicity, together with the arrival of more convenient antiretroviral drugs, led to a loss of interest. In this study, we evaluated the efficacy and tolerability of foscarnet in patients with late-stage HIV disease and no other therapeutic options. Methods Study design This open-label, single-centre, add-on pilot study examined the efficacy and safety of foscarnet induction therapy given for 6 weeks to patients with severe immunodeficiency, virological failure and multidrug-resistant HIV. Patients in whom pvl levels fell by at least 1 log 10 after 6 weeks were offered foscarnet maintenance therapy (MT) International Medical Press
2 A Canestri et al. Patients Patients were eligible if they had HIV-RNA values above 50,000 copies/ml and CD4 + T-cell counts below 100/mm 3 while on a stable antiretroviral regimen for at least 8 weeks (comprising at least four drugs), and if they had previously received at least three antiretroviral drug classes. Genotypic viral resistance had to include at least three TAMs, plus at least one mutation associated with resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and two primary mutations associated with resistance to protease inhibitors (PIs), according to the International AIDS Society-USA list (May 2004). The serum creatinine concentration had to be below 130 µmol/l at baseline. Study treatment Foscarnet induction therapy consisted of 5 g intravenously twice daily, concomitantly with 1,500 ml of normal saline, and calcium and phosphorus supplementation. This fixed dose corresponds to a median weight-based dose of 85 mg/kg twice daily on the basis of median weight of French HIV-infected patients with end-stage disease. Patients were hospitalized for a minimum of 10 days in order to assess tolerability. The only permitted changes in antiretroviral therapy were the addition of zidovudine (AZT; 300 mg twice daily) if AZT was not included in the baseline regimen (or the addition of stavudine [d4t] 30 mg twice daily in case of AZT intolerance), and tenofovir discontinuation in order to avoid potential additive nephrotoxicity. Induction therapy lasted 6 weeks. Patients who had at least a 1 log 10 fall in pvl at W6 were offered MT, consisting of foscarnet 5 g intravenously twice daily on two consecutive days per week. Ongoing antiretroviral therapy could be optimized before starting MT. Clinical and laboratory evaluations The patients had weekly clinical examinations and efficacy and safety assessments (biochemistry, viral load assay and CD4 + T-cell count). Plasma HIV-RNA was quantified with the Amplicor Monitor assay (v1.5; Roche Diagnostics, Meylan, France) which has a detection limit of 200 copies/ml. The RT gene was sequenced (codons 1 240) by means of automated population-based full-sequence analysis (ABI 3100 Genetic Analyser, PE Applied Biosystems, Foster City, CA, USA) at baseline, at the end of induction therapy, and monthly during maintenance therapy. All mutations in the RT and protease genes leading to amino acid changes were analysed, including mutations probably linked to foscarnet resistance [8,9,15]. Ophthalmoscopic examination, cytomegalovirus pp65 antigenaemia and blood culture on Lowenstein-Jensen medium were performed monthly. Endpoints for efficacy The primary endpoint was the proportion of patients experiencing a decrease in HIV-RNA of at least 1 log 10 at W6 compared with baseline. Secondary endpoints included changes in HIV RNA and in the CD4 + T-cell count at W6 compared with baseline; changes in HIV RNA and the CD4 + T-cell count during maintenance therapy; changes in the HIV genotypic resistance profile; and the safety and tolerability of foscarnet. Results Baseline characteristics A total of 11 men were enrolled between April 2004 and January One patient discontinued foscarnet at week 2 because of toxicity. The remaining 10 patients were assessable at W6. The median age of the 11 patients was 49 years (range: 33 75). All had been extensively treated, having been exposed to a median of 14 antiretroviral drugs (range: 11 16), including enfuvirtide (8/11) and tipranavir (7/11), over a median period of 12 years (range: ). The median baseline pvl was 5.18 log 10 copies/ml (range: ) and the median baseline CD4 + T-cell count was 10/mm 3 (range: 1 49). Ongoing antiretroviral therapy at baseline is shown in Table 1. Eight patients started AZT and one d4t concomitantly with foscarnet; the remaining two were already on AZT in their background regimen. All the patients had experienced AIDS-defining events, and nine patients had at least one active opportunistic infection at baseline, consisting of oesophageal candidiasis (n=3), disseminated Mycobacterium aviumintracellulare complex (MAIC) infection (n=2), lymphoma, CMV retinitis, HIV encephalitis, chronic diarrhoea and cryptosporidiosis (one case each). The median body weight was 65 kg (range: 56 74). Median creatinine clearance was 80 ml/min (range: ) and median haemoglobin was 9.8 g/dl (range: ); 5/11 patients (45%) had grade 1 anaemia. As shown in Table 2, all the patients harboured highly mutated viruses, with a median of 24 resistance mutations (range: 18 28), including nine associated with NRTI resistance (including four TAMs), two associated with NNRTI resistance and 12 associated with PI resistance. Five patients had mutations associated with enfuvirtide resistance. Four patients had resistance mutations reported to influence foscarnet susceptibility (K65R in patient 1, H208Y in patient 6, L228R in patient 10, and H208Y in patient 11) International Medical Press
3 Foscarnet salvage therapy in late-stage HIV Table 1. Characteristics at baseline, and evolution of HIV RNA and CD4 + T-cell count during induction and maintenance phases of foscarnet therapy Baseline characteristics W6 Maintenance therapy Background CD4 CD4 HIV-RNA VL log 10 CD4 HIV-RNA VL log 10 treatment cells/ HIV-RNA cells/ copies/ from Background ARV Reason for cells/ copies/ from Patients at baseline* mm 3 copies/ml mm 3 ml baseline optimization Time discontinuation mm 3 ml baseline 1 TZV 4 195, , TZV/ATZr/T20* W4 Failure 73 80, TZV/TPVr/T , < AZT switched W33 TMC , to d4t 3 TZV/TPV/SQV/ , , TMC-114 LPVr 4 TZV/ddI/TPV/ 14 52, , TZV/ddI/ATZ/ W29 TMC , SQV/LPVr/T20 APVr/T20* 5 ABC/d4T/3TC/ 2 106,000 Stop at W2 for oedema TPVr/T20 6 TZV-TPV , T20* W24 TMC , CBV/IDVr 5 150, , TC/d4T/TPV/ W12 Failure 17 84, APVr/T20* 8 CBV/APVr 6 138, < CBV/LPV/APV/ W14 Failure 29 25, T20* 9 TZV/APV/ATZ/ 1 4,580, , TMC-114 SQVr/T20 10 TZV/ddI/APVr , TMC TZV/APV/ATZ/ , , TMC-114 SQVr/T20 *8 weeks stable treatment except AZT or d4t addition or TDF discontinuation. CD4 + T-cell count expressed as absolute value. Recycled T20. 3TC, lamivudine; ABC, abacavir; APV, amprenavir; ATZ, atazanavir; AZT, zidovudine; CBV, zidovudine + lamivudine; d4t, stavudine; ddi, didanosine; IDV, indinavir; LPV, lopinavir; SQV, saquinavir; T20, enfuvirtide; TDF, tenofovir; TMC114, darunavir; TPV, tipranavir; TZV, zidovudine + lamivudine + abacavir; VL, viral load; W, week; X/r, boosted with low-dose ritonavir. Changes in HIV pvl and in the CD4 + T-cell count during induction therapy Eight patients had at least a 1-log 10 reduction in pvl at W6 (8/11, 73% in the intent-to-treat analysis; 8/10, 80% in the on-treatment analysis). The median change in HIV RNA from baseline was 1.39 log 10 copies/ml (range: 0.45 to 2.39) at W1, 1.99 log 10 copies/ml (range: 0.50 to 2.49) at W2, 1.82 log 10 copies/ml (range: 1.02 to 2.88) at W4, and 1.79 log 10 copies/ml (range: 2.88 to +0.11) at W6 (Figure 1). The median increase in the CD4 + T-cell count was 28/mm 3 (range: 0 111) at W6. Five patients (50%) who received the full induction course had CD4 + T-cell counts above 50/mm 3 at W6. Maintenance therapy Of the eight patients who had at least a 1 log 10 reduction in pvl at W6, six started foscarnet maintenance therapy, and the remaining two patients were enrolled in a Phase II trial of a new antiretroviral agent. Of these six patients, two discontinued foscarnet because of virological failure: patient 1 after 4 weeks and patient 7 after 12 weeks. The median change in pvl after 12 weeks of MT was 0.85 log 10 copies/ml (n=4) (range: 0.04 to 2.81), and the median change in the CD4 + T-cell count was +60 cells/mm 3 (range: ). At 24 weeks, three patients had received MT and had sustained pvl below 5,000 copies/ml. Changes in genotypic resistance No change in baseline mutations associated with NRTI or PI resistance was observed during either induction or maintenance therapy. One patient (2) had selected the K219R foscarnet mutation at the end of induction phase (W6; Table 2). Two patients (4 and 6) also harboured virus with this mutation at W16 and W24 of MT, respectively. Despite this, these three patients had virological response at the moment of resistance emergence ( 2.88, 0.77 and 2.55 log 10 ) and during the study (Table 1). No other change was observed on the RT gene sequences in the 11 patients. Antiviral Therapy 11:5 563
4 A Canestri et al. Table 2. Resistance mutations at baseline and during follow-up T20 mutations* Foscarnet mutations Patient RT inhibitor mutations* (baseline ) PI major mutations* (baseline ) Baseline Emergence (at) Baseline Emergence (at) 1 A62V, K65R, D67N, V75I, Y115F, L33F, M46I, V82C, I84V, L90M None K65R F116Y, V118I, Q151M, Y181C, M184V, G190A, T215V, K219Q 2 M41L, E44D, D67N, L74V, L100I, L33F, M46I, V82T V38A None K219R (W6) K103N, V118I, M184V, L210W, T215Y 3 D67N, T69D, V75I, F77L, K103N, Y181C, L33F, M46I, V82T, I84V, L90M None None Y115F, F116Y, V118I, Q151M, T215F, K219Q 4 M41L, D67N, T69D, V75M, V118I, V106M, L33F, M46I, V82T, I84V Q40H, None K219R (W16) Y188L, M184V, L210W, T215Y L45M 5 M41L, L74V, V118I, Y181C, M184V, G190A, M46L, V82C, L90M V38A/V None L210W, T215Y 6 M41L, E44D, D67N, L74I, V75T, V118I, M46I, I84V, L90M N42T, H208Y K219R (W24) M184V, G190A, T215F, K219Q N43D 7 M41L, E44D, D67N, V75M, F77L, V118I, L33F, M46I, V82A, I84V None G36D/G (W12) None M184V, Y188L, L210W, T215Y 8 M41L, E44D, D67N, L74I, Y181C, G190A, M46I, I84V, L90M V38A, None M184V, L210W, T215Y, K219N L44M 9 M41L, D67N, T69D, L74I, V75S, V118I, L33I, M46I, I84V, L90M None None Y181C, M184V, G190A, L210S, T215F, K219W 10 M41L, E44D, V118I, M184V, T215Y, L33F, M46I, I50V, V82T, L90M None L228R K103N, K219N 11 M41L, E44D, D67N, L74V, L100I, K103N, V118I, M184V, L210W, T215Y, K219N L33F, G48M, V82A, I84V, L90M None G36D (W6) H208Y *According to the IAS-USA List. No emergence of mutation during the study except for patient 3 with emergence of E203K, F227C, L228S polymorphisms at week 6. PI, protease inhibitor; RT, reverse transcriptase; W, week. Tolerability Only one patient discontinued foscarnet during the induction phase (W2), because of oedema with renal impairment and proteinuria; renal function recovered Figure 1. Changes in HIV plasma VL during the 6-weekinduction phase W1 W2 W3 W4 W5 W6 n VL, viral load; W, week days after foscarnet discontinuation. One patient had an infection associated with an intravenous device, which resolved on antimicrobial chemotherapy. No cases of renal impairment occurred during MT. AZT was discontinued in three patients for anaemia during induction phase (two grade 1 and one grade 2); they were switched to d4t. Median haemoglobin was 9.0 g/dl (range: ) at W6 and 7/11 patients (64%) had anaemia less than or equal to grade 2. One patient experienced genital ulceration that improved with local hygiene and treatment. Clinical events and follow-up No new AIDS-defining events occurred during the study period. Four patients had a clinical improvement in ongoing AIDS-related disorders (HIV encephalitis, cryptosporidiosis, CMV retinitis and severe chronic diarrhoea). Two patients (5 and 9) died of progressive HIV disease, 2 and 3 months after foscarnet discontinuation International Medical Press
5 Foscarnet salvage therapy in late-stage HIV Discussion In this pilot study of foscarnet therapy in HIV-infected patients with virological failure after exposure to at least three classes of antiretroviral drugs, pvl fell by a median of 1.79 log 10 copies/ml after 6 weeks of treatment, and the CD4 + T-cell count rose by a median of 28/mm 3. All patients had a sharp decline in pvl at W2, which was maintained at W6 in 9/10 patients. As foscarnet was added to a failing antretroviral regimen, it is very likely that the observed virological efficacy was due to foscarnet itself. Viral resistance was probably the main reason for virological failure at study entry, as the patients had adequate drug concentrations (not shown) but a median of 21 resistanceassociated mutations (range: 16 25). Similar results have been reported by Mathiesen et al. [14], who gave foscarnet salvage therapy to seven patients and observed a fall in pvl of 1.8 log 10 after 2 weeks. The precise mechanism of foscarnet action is unclear. All our patients had TAMs (median 4, range: 3 5), which increase HIV susceptibility to foscarnet [8,9]. Foscarnet is reported to restore susceptibility to thymidine analogues by attenuating the primerunblocking mechanism, which is one of the main mechanisms involved in NRTI resistance [8], and it is noteworthy that all our patients were receiving NRTIs at enrolment. Tachedjian et al. [9] have reported that mutations selected by foscarnet can restore AZT efficacy, and this is why we added AZT to each patient s drug regimen, if necessary. It is interesting to note that virological efficacy was maintained in our study even though four patients had baseline mutations thought to reduce foscarnet efficacy and another three patients acquired such mutations during treatment. Full-dose foscarnet therapy is unrealistic in the longterm because of potential nephrotoxicity and the inconvenience of intravenous infusion. Mathiesen et al. [14] used half the standard daily dose of foscarnet for maintenance therapy, but this resulted in a blunted virological response ( 0.6 log 10 ), probably owing to inadequate trough levels or acquisition of foscarnet resistance. We opted for an intermittent maintenance regimen, administering full-dose foscarnet on two consecutive days per week (then five days off), for reasons of patient convenience and virus cycling. The immunological benefit noted during the induction phase (5/10 assessable patients had CD4 + T-cell counts above 50/mm 3 ) persisted during maintenance therapy, and no clinical events were observed in these severely immunocompromised patients. Overall, foscarnet was well-tolerated. Renal toxicity occurred in one patient, but resolved rapidly after foscarnet discontinuation. Several strategies had been evaluated to significantly reduce viral replication in patients with multi-resistant viruses. Short-term treatment interruption followed by gigatherapy, including at least one active drug to which the patient has never been exposed, is associated with a virological benefit [16], whereas a 12-week treatment interruption failed to restore the antiviral efficacy of salvage gigatherapy comprising only previously used drugs, and was clinically deleterious [17 20]. By now, the best option for heavily treated patients is a regimen containing at least two active agents [1,2], but this is not always possible. Although our findings need to be confirmed in larger studies, they suggest that foscarnet might allow patients with very advanced HIV disease and no other treatment option to survive until new active therapies become available. References 1. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: Lalezari JP, Henry K, O Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: Tipranavir favored in RESIST-2. AIDS Patient Care STDS 2005, 19: Valdez HM, Kohlbrenner V, Mayers D. Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400 copies/ml when combined with a second active drug (T-20) in protease inhibitor experienced HIV+ patients. 3rd IAS conference on HIV Pathogenesis and Treatment. Rio de Janeiro July Abstract WeOa Katlama CCD, De Backer K, Lefebvre E, et al. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMC114-C213). 3rd IAS conference on HIV Pathogenesis and Treatment. Rio de Janeiro July Abstract WeOa LB Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19: Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41: Meyer PR, Matsuura SE, Zonarich D, et al. Relationship between 3 -azido-3 -deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 2003; 77: Tachedjian G, Mellors J, Bazmi H, Birch C, Mills J. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol 1996; 70: Devianne-Garrigue I, Pellegrin I, Denisi R, et al. Foscarnet decreases HIV-1 plasma load. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: Segondy M, Montes B, Delmas B, Leclercq C, Janbon F, Reynes J. Changes in HIV-1 RNA plasma level in patients treated with foscarnet. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: Balfour HH Jr, Fletcher CV, Erice A, et al. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob Agents Chemother 1996; 40: Antiviral Therapy 11:5 565
6 A Canestri et al. 13. Bergdahl S, Jacobsson B, Moberg L, Sonnerborg A. Pronounced anti-hiv-1 activity of foscarnet in patients without cytomegalovirus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: Mathiesen S, Roge BT, Weis N, Lundgren JD, Obel N, Gerstoft J. Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. AIDS 2004; 18: Mathiesen S, Dam E, Roge B, Laursen AL, Gerstoft J, Clavel F. Long-term foscarnet therapy remodels thymidine analogue mutations and reverse resistance to zidovudine. 14th International HIV Drug Resistance Workshop June 2005, Québec City, Canada. Abstract Katlama C, Dominguez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18: Ghosn J, Wirden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005; 19: Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18: Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349: Ruiz L, Ribera E, Bonjoch A, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003; 188: Accepted for publication 18 March International Medical Press
Management of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationPerspective Current Concepts in Antiretroviral Therapy Failure
International AIDS Society USA Perspective Current Concepts in Antiretroviral Therapy Failure Currently, the goal for the first and second, and possibly the third, antiretroviral regimen is the suppression
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationHIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe V Kouamou 1, J Manasa 1, D Katzenstein 1, A McGregor 1, CE Ndhlovu 1 & AT Makadzange 1. 1 University of Zimbabwe Introduction
More informationAntiviral Therapy 2011; 16: (doi: /IMP1851)
Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationI m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.
Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationActualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis
Actualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis Pr Vincent CALVEZ MD, PhD Dpt of Virology Pitié-Salpêtrière Hospital Paris, France Transmitted Drug Resistance in Low and
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationFrançois Raffi, 1 Christine Katlama, 2 Michael Saag, 3 Martin Wilkinson, 6 Jain Chung, 5 Lynn Smiley, 4 and Miklos Salgo 5
HIV/AIDS MAJOR ARTICLE Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO)
More informationThe US Food and Drug Administration has
NEW ANTIRETROVIRAL AGENTS FOR TREATMENT-EXPERIENCED PATIENTS * Roy M. Gulick, MD, MPH ABSTRACT Antiretroviral treatment regimens currently available for the treatment of the human immunodeficiency virus
More informationGenotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen
Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More information10 : 4. Introduction. R Sajithkumar, Kottayam. Mutations to select agents: Evolution:
10 : 4 HIV drug resistance and second line of ART Introduction The first response to the HIV epidemic identified as AIDS in 1981- was the feeling of helplessness. The cause of the illness was soon identified
More informationViral Resistance with Topical RT-Microbicides. Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles
Viral Resistance with Topical RT-Microbicides Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles verview What antiretrovirals (ARV) are being considered as candidate microbicides? How
More informationSubtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients
JAIDS Journal of Acquired Immune Deficiency Syndromes 31:121 127 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Rapid Communications Subtle Decreases in Stavudine Phenotypic Susceptibility Predict
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationDIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA:
Atazanavir (BMS-232632, ATV) Molecular Formula: C 38 H 52 N 6 O 7 H 2 SO 4 Molecular Weight: 704.9 Dosage Form(s): 100/150/200 mg capsule Route(s) of Administration: Oral Pharmacological Category: Indication(s):
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationResistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
Journal of Antimicrobial Chemotherapy Advance Access published December 9, 2009 J Antimicrob Chemother doi:10.1093/jac/dkp422 esistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
More informationAIDS, antiretroviral drugs, human immunodeficiency virus, mutations, pol gene, resistance
ORIGINAL ARTICLE Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure Véronique Schneider 1,Jérôme
More informationTitle. HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in
Title HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance October 13, 2004 Authors SY Rhee
More informationLa terapia dell infezione da HIV: passato, presente e futuro.
1 st Infectivology Today Paestum (SA) 14-15 maggio 2004 La terapia dell infezione da HIV: passato, presente e futuro. Prof. Adriano Lazzarin Università Vita-Salute San Raffaele, Milano Scuola di Specializzazione
More informationSpecial Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel
Special Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel In 1996 the International AIDS Society USA convened an international panel of experts
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationPatients with persistently low CD4 counts on antiretroviral
Predicting HIV Care Costs Using CD4 Counts From Clinical Trials Andrew Hill, PhD; and Kelly Gebo, MD, MPH Objective: To predict the effects of a new antiretroviral agent on the costs of care in a US HIV
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More information14 TH EUROPEAN HIV & HEPATITIS MEETING Abst#_O_06
14 TH EUROPEAN HIV & HEPATITIS MEETING 2016 Abst#_O_06 Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationNucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania
International Journal of Infectious Diseases (2009) 13, 81 89 http://intl.elsevierhealth.com/journals/ijid Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated
More informationGenotyping and Drug Resistance in Clinical Practice. Case Studies
Genotyping and Drug Resistance in Clinical Practice Case Studies 12/02 40 year old Hispanic male Dx with HIV 1995 + Hx of PCP > 1x, HepC Medication history: AZT, Crixivan, Videx EC, Sustiva, Zerit, Ziagen,
More informationHIV/AIDS CID 2003:37 (1 July) 113
MAJOR ARTICLE HIV/AIDS Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society USA Panel Martin S. Hirsch,
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationDifferentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail
HAART, HIV correlated pathologies and other infections Renato Maserati Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail Corresponding
More informationPersistent low level viraemia on third line ART
Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationMilan, Italy. Received 15 March 2002; returned 22 July 2002; revised 12 September 2002; accepted 27 September 2002
Journal of Antimicrobial Chemotherapy (2003) 51, 135 139 DOI: 10.1093/jac/dkg016 Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationChapter 49. Antiviral Agents
Chapter 49 Antiviral Agents Antiviral Drugs 1. Characters of Virus Viruses are obligate intracellular parasites their replication depends primarily on synthetic processes of the host cell. 2.Classification
More informationNational AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project T-20 (first fusion inhibitor) Nelfinavir 12 month data Latent HIV reservoir (integrated proviral DNA), CSF and protease inhibitors: preliminary data (ritonavir/saquinavir
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationInteractive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1
Antiviral Therapy 10:551 555 Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1 Mina John, Corey B Moore, Ian R James and Simon A Mallal* Centre for Clinical
More informationAntiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationHIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy
BRIEF COMMUNICATION HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy Authors Daniela Souza Araújo de Angelis 1 Adriana Fumie Tateno 1
More informationResponse to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network
Short communication Antiviral Therapy 12:1305 1310 Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network Marie-Laure Chaix 1 *, Loic Desquilbet
More informationVirologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 17, Number 3, 2001, pp. 203 210 Mary Ann Liebert, Inc. Virologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment
More informationTHERAPEUTIC DRUG MONITORING (TDM) Table 2. Dose Adjustment. Patient Drug (mg) Symptoms C trough -fold increase compared to MEC WT
1 The Sixth International Congress on Drug Therapy in HIV Infection took place in Glasgow, UK, on November 17-21, 2002. Pharmacological aspects of antiretroviral therapy were covered in both oral and poster
More information